Efficacy and safety of once-weekly somatrogon in adults with growth hormone deficiency: a randomized phase 3 study.

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and GHRH (Growth Hormone-Releasing Hormone) in this randomized controlled trial publication.

METHODS: A phase 3 randomized, double-blind, placebo-controlled study consisted of a 26-week double-blind period (Period 1), a 26-week open-label extension (OLE; Period 2), and a multi-year OLE (Period 3).

All patients received somatrogon in Periods 2 and 3.

Who Took Part

The abstract describes 389 patients taking part.

PubMed indexes the participants as young adults, adults, middle-aged adults and older adults, both men and women.

RESULTS: Of 389 patients screened, 202 were randomized, and 198 received treatment (somatrogon:133; placebo:65).

How the Study Was Run

The design is described as randomized, double-blind, open-label and placebo-controlled.

The patients were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.

Neither the patients nor the staff measuring them knew who was on Exogenous HGH, sermorelin & older GHRPs (why they're passed over), so expectations could not easily colour the readings.

Nothing was hidden in this open-label Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study: the patients and staff both knew the treatment.

Some patients received a placebo instead of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), giving a reference point.

What Was Measured

Primary endpoint was change in trunk fat mass (FM; baseline-Week 26).

Secondary endpoints included changes in total FM, lean body mass (LBM), percentage change in trunk FM, and trunk FM.

The subject headings attached to it are Human Growth Hormone, Body Composition, Insulin-Like Growth Factor I and Growth Hormone-Releasing Hormone.

Author keywords: Adult growth hormone deficiency, IGF-I, Lean body mass, Long-acting growth hormone and Somatrogon.

What This Means in Plain Language

The paper is a randomized, double-blind and open-label study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and GHRH (Growth Hormone-Releasing Hormone) in 389 patients.

With several hundred people or more, it is a fairly large study for this kind of research.

The publication is from 2026 (Pituitary), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page and the GHRH (Growth Hormone-Releasing Hormone) compound page, all human trials.